First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

Posted: October 17, 2020 at 4:17 pm

TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

More:
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

Related Posts